Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

ConferenceATG-207Neutral

AI Analysis

Summary

Antengene announced it will present the latest preclinical results of ATG-207, an αCD3-TGF-β bifunctional fusion protein, at ACR 2026. The available text does not include the data or presentation details.

Outcome Details

Antengene will present the latest preclinical results of ATG-207, an αCD3-TGF-β bifunctional fusion protein, at ACR 2026. No results are disclosed in the available text.

Importance:3/10

Sentiment:

0.10

preclinicalconferenceACR 2026bifunctional fusion proteinautoimmuneHong Kong

Related Companies

$GBCMD $TRAX

Read the original article

Published by PR Newswire Pharma on October 9, 2026 3:22 AM

Read Original